The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Abstract
CONTEXT: Insulin resistance is an almost universal finding in nonalcoholic fatty liver disease (NAFLD). This review outlines the evidence linking insulin resistance and NAFLD, explores whether liver fat is a cause or consequence of insulin resistance, and reviews the current evidence for treatment of NAFLD. EVIDENCE ACQUISITION: Evidence from epidemiological, experimental, and clinical research studies investigating NAFLD and insulin resistance was reviewed. EVIDENCE SYNTHESIS: Insulin resistance in NAFLD is characterized by reductions in whole-body, hepatic, and adipose tissue insulin sensitivity. The mechanisms underlying the accumulation of fat in the liver may include excess dietary fat, increased delivery of free fatty acids to the liver, inadequate fatty acid oxidation, and increased de novo lipogenesis. Insulin resistance may enhance hepatic fat accumulation by increasing free fatty acid delivery and by the effect of hyperinsulinemia to stimulate anabolic processes. The impact of weight loss, metformin, and thiazolidinediones, all treatments aimed at improving insulin sensitivity, as well as other agents such as vitamin E, have been evaluated in patients with NAFLD and have shown some benefit. However, most intervention studies have been small and uncontrolled. CONCLUSION: Insulin resistance is a major feature of NAFLD that, in some patients, can progress to steatohepatitis. Treatments aimed at reducing insulin resistance have had some success, but larger placebo-controlled studies are needed to fully establish the efficacy of these interventions and possibly others in reducing the deleterious effects of fat accumulation in the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Cited by
The PI3K/AKT Pathway in Obesity and Type 2 Diabetes
Huang, X., Liu, G., Guo, J., & Su, Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27173 · Cited by 1,673
“PI3K, Phosphoinositide 3-kinase; AKT, protein kinase B; T2DM, type 2 diabetes mellitus; RTKs, receptor tyrosine kinases; GPCR, G-protein-coupled receptors; PIP2, phosphatidylinositol 4,5-biphosphate; PIP3, phosphatidylinositol 3,4,5-triphosphate; PTEN, Phosphatase and tensin homologue; PDK1, phosphoinositide-dependent…”
BackgroundFrom NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Lipid-induced insulin resistance: unravelling the mechanism
Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60408-4 · Cited by 1,189
Identification and characterization of metabolically benign obesity in humans
Stefan, N. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.15.1609 · Cited by 1,049
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Littlejohns, T. J., Holliday, J., Gibson, L. M., Garratt, S., Oesingmann, N., Alfaro-Almagro, F., Bell, J. D., Boultwood, C., Collins, R., Conroy, M. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15948-9 · Cited by 812
Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance
Meex, R. C. R., & Watt, M. J. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.56 · Cited by 631
Bose, M., Lambert, J. D., Ju, J., Reuhl, K. R., Shapses, S. A., & Yang, C. S. (2008) · The Journal of Nutrition · doi:10.1093/jn/138.9.1677 · Cited by 613
De novo lipogenesis in health and disease
Ameer, F., Scandiuzzi, L., Hasnain, S., Kalbacher, H., & Zaidi, N. (2014) · Metabolism · doi:10.1016/j.metabol.2014.04.003 · Cited by 611
McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., & Roche, H. M. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00052 · Cited by 532
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H.-U. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 532
The role of hepatokines in metabolism
Stefan, N., & Häring, H.-U. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.258 · Cited by 500
Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis
Marra, F., Gastaldelli, A., Svegliati Baroni, G., Tell, G., & Tiribelli, C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.003 · Cited by 425
Hong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2014) · Hepatology · doi:10.1002/hep.26716 · Cited by 385
Molecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
Ota, T., Gayet, C., & Ginsberg, H. N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32752 · Cited by 376
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Genetic Syndromes of Severe Insulin Resistance
Semple, R. K., Savage, D. B., Cochran, E. K., Gorden, P., & O'Rahilly, S. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0020 · Cited by 358
Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome
KIM, C. H., & YOUNOSSI, Z. M. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.10.721 · Cited by 340
Abnormal Lipid and Glucose Metabolism in Obesity: Implications for Nonalcoholic Fatty Liver Disease
Parekh, S., & Anania, F. A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.055 · Cited by 340
Lee, Y.-H., Jung, K. S., Kim, S. U., Yoon, H.-J., Yun, Y. J., Lee, B.-W., Kang, E. S., Han, K.-H., Lee, H. C., & Cha, B.-S. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.051 · Cited by 340
Lee, Y., Kim, S. U., Song, K., Park, J. Y., Kim, D. Y., Ahn, S. H., Lee, B., Kang, E. S., Cha, B., & Han, K. (2016) · Hepatology · doi:10.1002/hep.28376 · Cited by 340
Animal models of NASH: Getting both pathology and metabolic context right
Larter, C. Z., & Yeh, M. M. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05543.x · Cited by 337
Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration
Sun, Z., Miller, R. A., Patel, R. T., Chen, J., Dhir, R., Wang, H., Zhang, D., Graham, M. J., Unterman, T. G., Shulman, G. I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2744 · Cited by 335
Non-alcoholic fatty liver disease and the metabolic syndrome: An update
Rector, R. S., Thyfault, J. P., Wei, Y., & Ibdah, J. A. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.185 · Cited by 332
Rector, R. S., Thyfault, J. P., Morris, R. T., Laye, M. J., Borengasser, S. J., Booth, F. W., & Ibdah, J. A. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00428.2007 · Cited by 321
“These findings would collectively result in less hepatocyte exposure to lipids and hyperinsulinemia, potent regulators of hepatic lipogenesis and inhibitors of VLDL secretion (22, 36, 43).”
BackgroundKantartzis, K., Peter, A., Machicao, F., Machann, J., Wagner, S., Königsrainer, I., Königsrainer, A., Schick, F., Fritsche, A., Häring, H.-U., et al. (2009) · Diabetes · doi:10.2337/db09-0279 · Cited by 303
Targher, G., & Byrne, C. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3093 · Cited by 297
The multiple roles of life stress in metabolic disorders
Kivimäki, M., Bartolomucci, A., & Kawachi, I. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00746-8 · Cited by 297
Trauner, M., Arrese, M., & Wagner, M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.10.007 · Cited by 291
Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease
Zhang, X.-Q. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1768 · Cited by 289
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
Chachay, V. S., Macdonald, G. A., Martin, J. H., Whitehead, J. P., O'Moore–Sullivan, T. M., Lee, P., Franklin, M., Klein, K., Taylor, P. J., Ferguson, M., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.024 · Cited by 289
Nonalcoholic fatty liver disease and aging: epidemiology to management.
Bertolotti, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14185 · Cited by 270
Aron-Wisnewsky, J., Minville, C., Tordjman, J., Lévy, P., Bouillot, J.-L., Basdevant, A., Bedossa, P., Clément, K., & Pépin, J.-L. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.04.022 · Cited by 255
Metabolic disturbances in non-alcoholic fatty liver disease
Byrne, C. D., Olufadi, R., Bruce, K. D., Cagampang, F. R., & Ahmed, M. H. (2009) · Clinical Science · doi:10.1042/cs20080253 · Cited by 258
Kontogianni, M. D., Tileli, N., Margariti, A., Georgoulis, M., Deutsch, M., Tiniakos, D., Fragopoulou, E., Zafiropoulou, R., Manios, Y., & Papatheodoridis, G. (2014) · Clinical Nutrition · doi:10.1016/j.clnu.2013.08.014 · Cited by 221
Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study
Bano, A., Chaker, L., Plompen, E. P. C., Hofman, A., Dehghan, A., Franco, O. H., Janssen, H. L. A., Murad, S. D., & Peeters, R. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1300 · Cited by 209
“In addition, the insulin resistance state associated with hypothyroidism (31) can contribute to NAFLD by concomitantly inducing “de novo” lipogenesis and generating a flux of free fatty acids from adipose tissue to the liver (32).”
BackgroundNonalcoholic fatty liver disease
Erickson, S. K. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800089-jlr200 · Cited by 194
Sex hormone-binding globulin and type 2 diabetes mellitus
Le, T. N., Nestler, J. E., Strauss, J. F., & Wickham, E. P. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.005 · Cited by 191
“NAFLD represents a spectrum of liver pathology resulting from abnormal fat accumulation in hepatocytes that may be driven, at least in part, by insulin resistance [88].”
BackgroundHajifathalian, K., Torabi Sagvand, B., & McCullough, A. J. (2019) · Hepatology · doi:10.1002/hep.30226 · Cited by 128
“NAFLD is associated with insulin resistance and increased triglyceride levels,(39-41) decreased adiponectin levels,(42-45) and metabolic syndrome.”
BackgroundKotronen, A., Seppälä-Lindroos, A., Bergholm, R., & Yki-Järvinen, H. (2007) · Diabetologia · doi:10.1007/s00125-007-0867-x · Cited by 126
Elevated Serum Aminotransferase Levels in Children at Risk for Obstructive Sleep Apnea
Kheirandish-Gozal, L., Sans Capdevila, O., Kheirandish, E., & Gozal, D. (2008) · Chest · doi:10.1378/chest.07-0773 · Cited by 118
Mild suppression of hyperinsulinemia to treat obesity and insulin resistance
Page, M. M., & Johnson, J. D. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.03.018 · Cited by 99
Nonalcoholic Fatty Liver Disease and Risk of Dementia: A Population-Based Cohort Study
Shang, Y., Widman, L., & Hagström, H. (2022) · Neurology · doi:10.1212/wnl.0000000000200853 · Cited by 85
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., et al. (2022) · Nutrients · doi:10.3390/nu14214673 · Cited by 84
Praet, S. F. E., Jonkers, R. A. M., Schep, G., Stehouwer, C. D. A., Kuipers, H., Keizer, H. A., & van Loon, L. J. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0169 · Cited by 80
Henney, A. E., Gillespie, C. S., Alam, U., Hydes, T. J., & Cuthbertson, D. J. (2023) · Nutrients · doi:10.3390/nu15102266 · Cited by 74
Zhang, S., Gu, Y., Bian, S., Lu, Z., Zhang, Q., Liu, L., Meng, G., Yao, Z., Wu, H., Wang, Y., et al. (2021) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa380 · Cited by 70
Promrat, K., Longato, L., Wands, J. R., & de la Monte, S. M. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00815.x · Cited by 66
Brouwers, B., Schrauwen-Hinderling, V. B., Jelenik, T., Gemmink, A., Havekes, B., Bruls, Y., Dahlmans, D., Roden, M., Hesselink, M. K. C., & Schrauwen, P. (2017) · Clinical Science · doi:10.1042/cs20170261 · Cited by 59
The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis
Mouchiroud, M., Camiré, É., Aldow, M., Caron, A., Jubinville, É., Turcotte, L., Kaci, I., Beaulieu, M.-J., Roy, C., Labbé, S. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129492 · Cited by 57
Arrese, M., & Karpen, S. J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.2 · Cited by 54
Complement Alternative Pathway Activation in Human Nonalcoholic Steatohepatitis
Segers, F. M., Verdam, F. J., de Jonge, C., Boonen, B., Driessen, A., Shiri-Sverdlov, R., Bouvy, N. D., Greve, J. W. M., Buurman, W. A., & Rensen, S. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110053 · Cited by 50
Holt, H. B., Wild, S. H., Postle, A. D., Zhang, J., Koster, G., Umpleby, M., Shojaee-Moradie, F., Dewbury, K., Wood, P. J., Phillips, D. I., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0629-9 · Cited by 48
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Incretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40
Russo, M. F., Lembo, E., Mari, A., Angelini, G., Verrastro, O., Nanni, G., Pompili, M., Raffaelli, M., Vecchio, F. M., Bornstein, S. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa892 · Cited by 28
Serum osteocalcin levels in children with nonalcoholic fatty liver disease
Amin, S., El Amrousy, D., Elrifaey, S., Gamal, R., & Hodeib, H. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001768 · Cited by 18
Azulai, S., Grinbaum, R., Beglaibter, N., Eldar, S. M., Rubin, M., Ben-Haroush Schyr, R., Romano-Zelekha, O., & Ben-Zvi, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051144 · Cited by 13
Varmazyar, I., Monazzami, A. A., Moradi, M., & McAinch, A. J. (2024) · BMC Sports Science, Medicine and Rehabilitation · doi:10.1186/s13102-024-00972-9 · Cited by 7
Sharma, S., Stine, J. G., Verbeek, T., & Bezinover, D. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.07.020 · Cited by 5
Huang, N., Su, X., Yu, T., Wu, X., Lu, B., Sun, W., Yao, L., Wang, M., Wang, Y., Wu, W., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1420088 · Cited by 4
Metadata
- Authors
- Utzschneider, K. M., & Kahn, S. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-12-01
- Volume
- 91
- Issue
- 12
- Pages
- 4753-4761
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2160832007
- Cited by
- 856
- References
- 116
- FWCI
- 24.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.